NEW YORK — Interpace Diagnostics said today that it has signed coverage contracts with three independent Blue Cross Blue Shield plans in Alabama, Arkansas, and Arizona for its ThyGeNext and ThyraMir thyroid cancer detection assays on an in-network basis.
The BCBS plans cover nearly 5 million individuals in the three states, Parsippany, New Jersey-based Interpace said.
The ThyGeNext and ThyraMir tests are used to determine the presence or absence of cancer in thyroid nodules. When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier to offer physicians actionable test results, according to Interpace.
"Interpace continues adding contracts and expanding the accessibility of its molecular thyroid products to Blue Cross Blue Shield members across the country," Interpace CEO Jack Stover said in a statement. "The addition of these BCBS plans as in-network providers under contract is beneficial to their members and represents another important milestone."